Jack Henningfield, Ph.D.

Vice President, Research, Health Policy, and Abuse Liability


Jack E. Henningfield is one of the world’s leading experts on addiction, and the behavioral, cognitive, and central nervous system (CNS) effects of drugs. He has received numerous awards for his research and policy contributions to the understanding and control of addiction. In his role at PinneyAssociates, Jack:

  • Counsels clients on assessment of the abuse liability of new CNS-acting drugs and formulations, and develops assessments of abuse potential (8 Factor Analyses) to support potential Controlled Substances Act scheduling recommendations
  • Leads assessment of the tamper resistance of novel formulations, and development of risk management approaches
  • Counsels clients on finding regulatory pathways for psychedelics, cannabinoids, and CNS-active dietary supplements such as kratom and some cannabinoids
  • Liaises with the FDA on issues concerning drug scheduling and addiction/abuse liability and presents frequently to FDA Advisory Committees on behalf of product sponsors


Jack joined PinneyAssociates in September 1996 after 16 years of public service at the Intramural Research Program of the National Institutes of Health’s National Institute on Drug Abuse (NIDA), where he led abuse potential assessments and developed drug scheduling recommendations in frequent collaboration with the FDA and DEA. He has served on numerous US Government agency committees and international committees including more than 13 years on a World Health Organization (WHO) expert committee.

At NIDA, he served as Chief of the Human Performance Laboratory (1984-1985), Chief of the Biology of Dependence and Abuse Potential Assessment Section (1985-1996), and Chief of the Clinical Pharmacology Research Branch (1989-1996) and directed the Minority Recruitment and Training Program (1990-1996). He was a frequent contributor to NIDA’s reports to Congress, Reports of the Surgeon General, and provided congressional testimonies on behalf of NIDA.

Since leaving NIDA he has served as a Special Government Employee to the FDA Center for Drug Evaluation and Research (2009-2014) and Center for Tobacco Products (2010-2013).
Jack has been a member of the Johns Hopkins University School of Medicine faculty since 1978 and is presently Adjunct Professor of Behavioral Biology at the Medical School’s Department of Psychiatry and Behavioral Sciences, and an affiliated faculty with The Johns Hopkins Bloomberg School of Public Health. Jack is also a former adjunct faculty member with the Program of Toxicology at the University of Maryland at Baltimore.

Throughout his career Jack has contributed to numerous comments to FDA on topics including prescribing of opioids for chronic pain, development and regulation of abuse-deterrent opioid formulations, and regulation of nicotine delivery systems. Jack’s research has resulted in the writing of numerous books and monographs, and over 450 published papers on myriad topics in public health, pharmacology, and addiction. He has received numerous national and international awards recognizing his scientific and public health leadership efforts.


  • Postdoctoral research fellow at the University of Minnesota and at the Johns Hopkins University School of Medicine, Behavioral Pharmacology Research Unit
  • Postdoctoral training supported by National Council on Alcoholism Fellowship at the University of Minnesota, Department of Psychiatry
  • Received his doctorate in experimental psychology with a pharmacology supporting program from the University of Minnesota’s Psychopharmacology Training Program, with a focus on addiction, CNS medications, preclinical abuse liability assessment, and drug addiction control
  • Graduated summa cum laude from the University of Minnesota with a bachelor’s in psychology